Compare Entegris Inc (ENTG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Recursion Pharmaceuticals Inc — how do they compare? Entegris Inc trades at $164.91 (market cap $24.78B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: Entegris Inc is far larger — about 11.6× Recursion Pharmaceuticals Inc's market cap, and Entegris Inc pays a 0.25% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| ENTG | RXRX | |
|---|---|---|
Market Cap | $24.78B | $2.14B |
Volume | 2,648,320 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $184.00 | $6.79 |
52-Week Low | $68.80 | $2.84 |
Typical Hold Time | 41 Days | 22 Days |
Enterprise Value | $27.99B | $1.66B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $166.32, down 0.34% on the day, with strong technical momentum showing bullish moving averages and key resistance at $168. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected October 29. Revenue remains stable at $3.2B (2025) with improving net margins from 5.12% (2023) to 7.37% (2025), though valuation ratios appear elevated with P/E at 83.16.
Wall Street maintains strong bullish sentiment with 70% buy ratings and $182.43 consensus price target, representing 9.7% upside. Key risks include high debt levels ($3.98B) and semiconductor industry cyclicality. The upcoming Q3 earnings and November Investor Day will be critical catalysts for near-term direction.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
